The Real Bottlenecks in AI Drug Discovery
rand_longevity · x · 2026-07-17
This shares a long interview/podcast on AI drug discovery, addressing the core question: why has the industry invested billions without a single AI-designed drug approved yet? Centered on Retro Bio's practices, the conversation covers tech roadmaps from proteins to cells, "virtual cells," and clinical validation.
The content highlights several key takeaways: the industry entered a new phase post-AlphaFold, but true success hinges not on isolated modeling, but on black-box data, experimental closed-loops, and building capabilities to go "from protein to cell." It also touches on infrastructure trends like AI co-scientists and AWS for biotech, as well as the fine line between "real progress" and "overhype."
Related event: The Real Bottlenecks in AI Drug Discovery(2 posts)→
More from Companies & People
- Hugging Face schedules its first Japan event in Tokyo this Thursday — LysandreJik · 2026-07-21
- Chamath says open-sourcing Grok would push AI margins from models to infra and apps — Dan_Jeffries1 · 2026-07-21
- Presidio acquires LookingPoint to expand AI, cloud and cybersecurity — TechNadu · 2026-07-21
- As software gets easier to build, the real bar rises to what to make and why — HankYeomans · 2026-07-21
- Hugging Face chief says U.S. guardrails forced a Chinese model into a real cyber defense — Nunki08 · 2026-07-21
- Anthropic turns a Jacobian conjecture joke into a workplace meme — gerardsans · 2026-07-21